Voyager Therapeutics (VYGR) investor relations material

Executive summary

• Focused on developing genetic medicines for neurological diseases, with a pipeline targeting Alzheimer's, Friedreich's ataxia, Parkinson's, and other CNS disorders, leveraging proprietary TRACER AAV and NeuroShuttle platforms.

• Advanced two tau-targeted Alzheimer's programs: VY1706 (tau-silencing gene therapy) and VY7523 (anti-tau antibody), with clinical trial initiations and data readouts expected in late 2026 and 2027.

• Presented positive preclinical data for VY1706, showing up to 75% tau protein reduction in primate models.

• Multiple collaborations with Neurocrine, Novartis, Alexion, and Transition Bio, providing significant non-dilutive funding and future milestone/royalty potential.

Financial highlights

• Collaboration revenue was $3.2M for Q2 2026, down from $5.2M in Q2 2025; $5.8M for the first half of 2026, down from $11.7M in the prior year period.

• Net loss for Q2 2026 was $24.5M (vs. $33.4M in Q2 2025); net loss for the first half of 2026 was $52.4M (vs. $64.4M in 2025).

• Research and development expenses decreased to $22.0M in Q2 2026 (from $31.3M), reflecting program prioritization.

• General and administrative expenses were $7.5M in Q2 2026 (down from $10.5M), attributed to restructuring.

• Cash, cash equivalents, and marketable securities totaled $148.8M as of June 30, 2026.

Outlook and guidance

• Existing cash and expected collaboration reimbursements are projected to fund operations into 2028.

• Continued focus on clinical advancement of Alzheimer's programs and strategic collaborations.

• VY7523 tau PET imaging data and VY1706 clinical dosing in Alzheimer's expected in Q4 2026.

• Initial acute safety data for VY1706 anticipated in early 2027, with biomarker data in H2 2027.

• Neurocrine plans to initiate a clinical trial for NBIB-223 in Friedreich's ataxia in H2 2026, pending FDA clearance.